PSO wants a 15% rate hike, adding $25 to monthly bills by July 2026. Critics say the $1.2 billion expansion is tied to data ...
Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback